linjc16/ctgov huggingface dataset:
Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects

Study Overview
=================
Brief Summary
-----------------
Few data and small numbers affect the inflammatory profile of Dunnigan patients. The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals. However, in these studies, several confounding factors were not taken into account such as smoking, an underlying chronic inflammatory disease such as diabetes and could limit the interpretation of the results. There is no other observation of the anti-inflammatory status of these patients.

Official Title
-----------------
Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects

Conditions
-----------------
Lipodystrophy, Dunnigan Syndrome

Intervention / Treatment
-----------------
* Biological: Bood and urine sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult subject (>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study). Person affiliated to or beneficiary of a social security scheme. Free, informed and written consent signed by the participant and the investigator. Exclusion Criteria: - Minor Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study Previous known diabetes Pregnant woman Woman who gave birth less than 6 months ago Breastfeeding in progress Participation in other research that may have an impact on the evaluation of the main judgment criteria Hemoglobin b level < 7 mg/dl or < 9-10 mg/dl for patients with cardiovascular or respiratory pathology. Proven inflammatory pathologies Anti-inflammatory treatment: taking corticosteroids in the last 3 months. Active smoking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: sampling and clinical data collection<br>Participant blood and urine are sampled for inflammatory signal analysis | Biological: Bood and urine sampling<br>* Bood and urine sampling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pro-inflammatory markers | blood sample and dosage of pro inflammatory cytokine | inclusion day |
Psycho-social Impact of Anti-NMDAR Encephalitis

Study Overview
=================
Brief Summary
-----------------
NMDA receptor encephalitis is a rare neurological autoimmune disease with severe neuropsychiatric symptoms, but a typically good functional neurological outcome. The majority of patients experience long-term cognitive, psychological and social impairments that have significant consequences for their well-being and quality of life. However, as the disease was only recently discovered (Dalmau and al. Annals of neurology, 2007), this psycho-social impact has not been studied systematically and the resulting consequences for patients are not adequately appreciated. The proposed study aims at characterizing the cognitive and psycho-social long-term consequences of this rare disease. Our main hypothesis is that NMDAR encephalitis has a persistent and clinically relevant impact on the patients' long-term cognitive, psychological and social well-being. Furthermore, we hypothesize that longterm subjective outcomes depend on both internal and external factors, such as acute disease course, access to post-acute care, caregiver support, personal coping strategies, or access to health education resources and peer group support.

Official Title
-----------------
Psycho-social Impact of Anti-NMDAR Encephalitis

Conditions
-----------------
NMDAR Antibody-associated Auto-immune Encephalitis

Intervention / Treatment
-----------------
* Other: standardized and validated surveys


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with anti-NMDAR encephalitis Year ≥ 18 ans Patients affiliated to the social security scheme Exclusion Criteria: Patients with no anti-NMDAR encephalitis Minor patient Patient under guardianship or curatorship Patient with preexisting neurological symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: standardized and validated surveys|To evaluate the cognitive and psycho-social long term impact of a NMDAR encephalitis, we will collect the data using specific interview assessments such as the PROMS (Patient-reported Outcome Measures Information System) and PREMS (Patient-reported experiences measures) as well as we will check the cognitive performance in order to combine the expertise from clinical neurology, social & health psychology|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive and psycho-social analyses of patients with NMDAR encephalitis. | The analyze will focus on the post-acute phase of the disease. | At study completion in an average of 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
auto-immune encephalitis, NMDA receptor encephalitis, Health-related quality of life, psyco-social impact, cognitive consequence
Cutaneous Sensory Block Area of the Subcostal Ultrasound-Guided Transversus Abdominis Plane Block

Study Overview
=================
Brief Summary
-----------------
Patients planned for elective laparoscopic cholecystectomy received a peroperative ultrasound-guided subcostal transversus abdominis plane block (USTAP) at the beginning of the procedure. At T90 minutes after the end of anaesthesia the cutaneous sensory block area (CSBA) was measured using cold sensation and mapped with a sterile marker. The CSBA was photodocumented and the area calculated.

Official Title
-----------------
Cutaneous Sensory Block Area of the Subcostal Ultrasound-Guided Transversus Abdominis Plane Block

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Planned for elective laparoscopic cholecystectomy, age 18 or older, written and verbal consent Exclusion Criteria: Non-compliant due to language or psychiatric disease, previous surgery to the upper abdomen, incisional hernia, pregnancy, sensory deficit of the abdomen or thorax.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients planned for cholecystectomy<br>Patients planned for elective laparoscopic cholecystectomy received a peroperative ultrasound-guided transversus abdominis plane (TAP) block at the beginning of the procedure. | Procedure: Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)<br>* US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cutaneous Sensory Block Area | The area of the dermis which is blocked to sensory stimulus such as pain, heat and cold. | 90 minutes postoperatively or 150 minutes after US-TAP application | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transversus abdominis plane block
The Significance of Postoperative Muscle Wasting in Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
To assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.

Detailed Description
-----------------
Previous studies have revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, is a poor prognostic factor following surgery. However, research focusing on postoperative muscle wasting and its influence on the prognosis of resectable pancreatic cancer (PC) is limited. Investigators retrospectively reviewed 208 patients who underwent pancreatectomy for PC at the National Cheng Kung University Hospital (NCKUH) between June 2002 and April 2020. Clinical information regarding patient characteristics, pathological parameters, and biochemical features was collected from all patients using electronic medical records (EMRs) under an IRB-approved protocol (B-ER-110-420) at NCKUH. Preoperative psoas major area and the degree of muscle reduction at 3 months postoperatively were calculated using computed tomography to define sarcopenia and drastic muscle wasting. Patients were assigned to two groups based on sarcopenia or drastic muscle wasting, and compared for postoperative morbidity, disease free survival (DFS), and overall survival (OS).

Official Title
-----------------
National Cheng Kung University Hospital

Conditions
-----------------
Pancreatic Cancer

Intervention / Treatment
-----------------
* Procedure: pancreatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of pancreatic cancer Must be able to undergo pancreatectomy Must be able to undergo pre- and post-operative abdominal computed tomography scan Exclusion Criteria: Unresectable pancreatic cancer

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: pancreatectomy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival was measured as the period between the date of resection and the date of the last follow-up or death. | 10 years | 
| Disease-free survival | Disease-free survival was defined as the duration from resection to cancer relapse (local, peritoneal recurrence, or distal metastasis). | 10 years |
Microecology and Host Immunity in Patients With Severe COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the prognosis of patients with severe COVID-19.

Detailed Description
-----------------
Methods: Bronchoalveolar lavage specimens of patients with severe COVID-19 were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.

Official Title
-----------------
Microecology and Host Immunity in Patients With Severe COVID-19 Infection

Conditions
-----------------
Microbiome,Immune Function, Critically Ill

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Respiratory distress, respiratory rate ≥ 30 times/minute 2) At rest, oxygen saturation ≤ 93% 3）PaO2/FiO2 ≤300mmHg 4) Shock 5) Respiratory failure requires mechanical ventilation 6) Complicated with other organ failure requires ICU monitoring and treatment 7) Or in case of any of the following conditions, even if none of the above conditions is found, it is also managed as a critical case: ① pulmonary imaging shows that the lesion has significantly progressed more than 50% within 24-48 hours; ② Age>60 years old; ③ Complicated with serious chronic diseases (including diabetes, hypertension, coronary heart disease, malignant tumor, structural lung disease, pulmonary heart disease and immunosuppressed population) Exclusion Criteria: 1) Pregnant women 2) Age<18 3) Mental disorders 4) Patients with long-term mechanical ventilation for more than 60 days 5) Disagreement group researcher

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death | mortality | 28 day |
SMART@Home Feasibility Trial

Study Overview
=================
Brief Summary
-----------------
The proposed research addresses the limitations or lack of a digital platform to provide remote care of medically complex patients. Previous attempts have had poor clinical validity and suffered lack of patient engagement. The study team will deconstruct the previously implemented SMART platforms to create a roadmap, platform, and template to guide clinicians to create new tools. Results from Phase 1 of this project highlighted the need for connectivity between the SMART@Home app and Bluetooth-enable devices to provide objective disease activity data as well as integration with Epic electronic health record so that providers can use the data to inform treatment planning and decision making. A subsequent pilot user validation trial is also needed to confirm development goals were met. Conducting a pilot user validation trial of the SMART@Home asthma tracker, spirometer, and action plan is the purpose of the next phases of this study.

Official Title
-----------------
Self-Management Assistance for Recommended Treatment (SMART)@Home Care

Conditions
-----------------
Asthma, Asthma in Children

Intervention / Treatment
-----------------
* Behavioral: SMART@Home


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with a chronic medical condition requiring regular treatment, i.e., asthma Ages 11-17 English fluency for patient and caregiver Exclusion Criteria: Diagnosis of pervasive developmental disorder in patient or caregiver as determined by medical chart review Diagnosis of serious mental illness (e.g., schizophrenia) in patient or caregiver as determined by medical chart review

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SMART@Home<br>Use of the SMART@Home app for medication and symptom tracking | Behavioral: SMART@Home<br>* Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medication adherence | Medication adherence will be measured using electronic monitoring of medications indicated being taken in the SMART-IBD app | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma
Synovial Sarcoma Registry / Biospecimen Repository

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.

Detailed Description
-----------------
This study will enroll patients with a diagnosis of Synovial Sarcoma. Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records. At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes. Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study. Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs). Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant.

Official Title
-----------------
Synovial Sarcoma Registry and Biospecimen Repository

Conditions
-----------------
Synovial Sarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females of any age Reported diagnosis of synovial sarcoma Informed consent from subject (aged ≥18 years) or parent/guardian Exclusion Criteria: Individuals with sarcomas that do not fit the definition of those considered for this registry Individuals who are unwilling to participate Individuals who are unwilling or unable to provide written consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with synovial sarcoma | Number of patients with synovial sarcoma | Up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
registry, biorepository, sarcoma, oncology, cancer, rare tumor
An Observational Study of Local Relapse After High Grade Osteosarcoma

Study Overview
=================
Brief Summary
-----------------
multicenter retrospective and prospective study in patients with high-grade osteosarcoma

Detailed Description
-----------------
This is a multicenter retrospective and prospective study that will analyze all cases with of diagnosis of local relapse in high-grade osteosarcoma from 01 January 1980 and all new cases referring to each participant site.

Official Title
-----------------
An Observational Study of Local Relapse After High Grade Osteosarcoma

Conditions
-----------------
Osteosarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who experienced LR as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases Adequate patient compliance to follow-up visits Written informed consent prior to any study-specific analysis and/or data collection No age limits Exclusion Criteria: Cases of LR demonstrated after > 3 months after metastatic disease Impossibility to ensure adequate compliance
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post local relapse survival | the aim of the study is to analyse the factors influencing post local relapse survival | 24 months follow up |
Epigallocatechin Gallate and Other Antural Compounds in HPV Infections

Study Overview
=================
Brief Summary
-----------------
The investigators enroll patients with a PAP-test cytology reporting LSIL or ASCUS. Pateitns undergo HPV-DNA test for screening. Patients are treated with Epigallocatechin galalte, hyaluronic acid, folic acid and Vitamin B12 by oral route. After three months of treatment PAP-test and HPV-DNA test will be repeated.

Official Title
-----------------
Treatment With Epigallcoatechin Gallate, Hyaluronic Acid, Folic Acid and Vitamin B12 in Women HPV Positive With Abnormal Cytology Tests

Conditions
-----------------
Papilloma-induced Cervical Lesions

Intervention / Treatment
-----------------
* Drug: EGCG, FA, HA, B12


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positivity to HPV-DNA test PAP-test reporting LSIL or ASCUS Exclusion Criteria: HPV-related pathologies or complicances apart from LSIL or ASCUS Diagnosis of cancer

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Patients decide wheter to receive the experimental treatment or to undergo routine clinical practice.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>The patients in this group undergo treatment with Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg and Folic acid 400mcg by oral route once per day. | Drug: EGCG, FA, HA, B12<br>* Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg<br>|
| No Intervention: Control<br>The patients in this group follow the routine clinical practice, namely the clinical monitoring. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positivity to HPV infection | The outcome consists of the number of negative DNA-test obtained in patients previously positive. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of lesions | The outcome consists of the number of negative PAP-tests obtained in patients previously positive. | 3 months | 
| Lesions-related symptmos | The ouctome includes the occurrence of bleeding, flogosis, or sexual pain. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EGCG, HPV, Folic acid, Hyaluronic acid, Vitamin B12, LSIL